TY - JOUR
T1 - Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19
AU - Norris, Tom
AU - Razieh, Cameron
AU - Yates, Thomas
AU - Zaccardi, Francesco
AU - Gillies, Clare L
AU - Chudasama, Yogini V
AU - Rowlands, Alex
AU - Davies, Melanie J
AU - McCann, Gerry P
AU - Banerjee, Amitava
AU - Docherty, Annemarie B
AU - Openshaw, Peter J M
AU - Baillie, J Kenneth
AU - Semple, Malcolm G
AU - Lawson, Claire A
AU - Khunti, Kamlesh
N1 - Funding Information:
Acknowledgments. This work uses data provided by patients and collected by the National Health Service as part of their care and support (#DataSavesLives). The authors are grateful to the 2,648 frontline National Health Service clinical and research staff and volunteer medical students who collected these data in challenging circumstances and the generosity of the participants and their families for their individual contributions in these difficult times. The authors also acknowledge the support of Jeremy J. Farrar (Wellcome Trust, London, U.K.) and Nahoko Shindo (World Health Organization, Geneva, Switzerland). Funding. This work was supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (BRC), NIHR Applied Research Collaboration–East Midlands (ARC-EM), the UK Research and Innovation Department of Health and Social Care (UKRI-DHSC) COVID-19 Rapid Response Rolling Call (grant MR/V020536/1), Health Data Research (HDR)-UK (grant HDRUK2020.138), the NIHR (award CO-CIN-01), the Medical Research Council (MRC) (grant MC_PC_19059), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at the University of Liverpool.
Funding Information:
The funder/sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Duality of Interest. K.K. is supported by the NIHR ARC-EM and T.Y. by the NIHR Leicester BRC. K.K. is director for the University of Leicester Centre for Black and Minority Ethnic Health, trustee of the South Asian Health Foundation, national NIHR ARC lead for ethnicity and diversity, member of Independent Scientific Advisory Group for Emergencies (SAGE), and chair of the SAGE subgroup on ethnicity and COVID-19. G.P.M. is supported by an NIHR Research Professorship (2017-08-ST2-007). M.G.S. is a member of HMG (Her Majesty's Government) SAGE COVID-19 and reports grants from the DHSC, NIHR, MRC, and NIHR HPRU in Emerging and Zoonotic Infections, University of Liverpool, during the conduct of the study. M.G.S. reports other support from Integrum Scientific LLC outside the submitted work. No other potential conflicts of interest relevant to this article were reported. Author Contributions. T.N. wrote the first draft of the manuscript. T.N. and C.R. analyzed the data. T.N., C.R., C.A.L., and K.K. conceived of the study. T.Y., F.Z., C.L.G., Y.V.C., A.R., M.J.D., G.P.M., A.B., A.B.D., P.J.M.O., J.K.B., M.G.S., C.A.L., and K.K. reviewed the manuscript and provided important edits. C.A.L. and K.K. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Funding Information:
This work was supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (BRC), NIHR Applied Research Collaboration-East Mid¬lands (ARC-EM), the UK Research and Innovation Department of Health and Social Care (UKRI- DHSC) COVID-19 Rapid Response Rolling Call (grant MR/V020536/1), Health Data Research (HDR)-UK (grant HDRUK2020.138), the NIHR (award CO-CIN-01), the Medical Research Coun¬cil (MRC) (grant MC_PC_19059), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at the Univer¬sity of Liverpool.
Publisher Copyright:
© 2022 by the American Diabetes Association.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - OBJECTIVE: To investigate the association between admission blood glucose levels and risk of in-hospital cardiovascular and renal complications.RESEARCH DESIGN AND METHODS: In this multicenter prospective study of 36,269 adults hospitalized with COVID-19 between 6 February 2020 and 16 March 2021 (N = 143,266), logistic regression models were used to explore associations between admission glucose level (mmol/L and mg/dL) and odds of in-hospital complications, including heart failure, arrhythmia, cardiac ischemia, cardiac arrest, coagulation complications, stroke, and renal injury. Nonlinearity was investigated using restricted cubic splines. Interaction models explored whether associations between glucose levels and complications were modified by clinically relevant factors.RESULTS: Cardiovascular and renal complications occurred in 10,421 (28.7%) patients; median admission glucose level was 6.7 mmol/L (interquartile range 5.8-8.7) (120.6 mg/dL [104.4-156.6]). While accounting for confounders, for all complications except cardiac ischemia and stroke, there was a nonlinear association between glucose and cardiovascular and renal complications. For example, odds of heart failure, arrhythmia, coagulation complications, and renal injury decreased to a nadir at 6.4 mmol/L (115 mg/dL), 4.9 mmol/L (88.2 mg/dL), 4.7 mmol/L (84.6 mg/dL), and 5.8 mmol/L (104.4 mg/dL), respectively, and increased thereafter until 26.0 mmol/L (468 mg/dL), 50.0 mmol/L (900 mg/dL), 8.5 mmol/L (153 mg/dL), and 32.4 mmol/L (583.2 mg/dL). Compared with 5 mmol/L (90 mg/dL), odds ratios at these glucose levels were 1.28 (95% CI 0.96, 1.69) for heart failure, 2.23 (1.03, 4.81) for arrhythmia, 1.59 (1.36, 1.86) for coagulation complications, and 2.42 (2.01, 2.92) for renal injury. For most complications, a modifying effect of age was observed, with higher odds of complications at higher glucose levels for patients age <69 years. Preexisting diabetes status had a similar modifying effect on odds of complications, but evidence was strongest for renal injury, cardiac ischemia, and any cardiovascular/renal complication.CONCLUSIONS: Increased odds of cardiovascular or renal complications were observed for admission glucose levels indicative of both hypo- and hyperglycemia. Admission glucose could be used as a marker for risk stratification of high-risk patients. Further research should evaluate interventions to optimize admission glucose on improving COVID-19 outcomes.
AB - OBJECTIVE: To investigate the association between admission blood glucose levels and risk of in-hospital cardiovascular and renal complications.RESEARCH DESIGN AND METHODS: In this multicenter prospective study of 36,269 adults hospitalized with COVID-19 between 6 February 2020 and 16 March 2021 (N = 143,266), logistic regression models were used to explore associations between admission glucose level (mmol/L and mg/dL) and odds of in-hospital complications, including heart failure, arrhythmia, cardiac ischemia, cardiac arrest, coagulation complications, stroke, and renal injury. Nonlinearity was investigated using restricted cubic splines. Interaction models explored whether associations between glucose levels and complications were modified by clinically relevant factors.RESULTS: Cardiovascular and renal complications occurred in 10,421 (28.7%) patients; median admission glucose level was 6.7 mmol/L (interquartile range 5.8-8.7) (120.6 mg/dL [104.4-156.6]). While accounting for confounders, for all complications except cardiac ischemia and stroke, there was a nonlinear association between glucose and cardiovascular and renal complications. For example, odds of heart failure, arrhythmia, coagulation complications, and renal injury decreased to a nadir at 6.4 mmol/L (115 mg/dL), 4.9 mmol/L (88.2 mg/dL), 4.7 mmol/L (84.6 mg/dL), and 5.8 mmol/L (104.4 mg/dL), respectively, and increased thereafter until 26.0 mmol/L (468 mg/dL), 50.0 mmol/L (900 mg/dL), 8.5 mmol/L (153 mg/dL), and 32.4 mmol/L (583.2 mg/dL). Compared with 5 mmol/L (90 mg/dL), odds ratios at these glucose levels were 1.28 (95% CI 0.96, 1.69) for heart failure, 2.23 (1.03, 4.81) for arrhythmia, 1.59 (1.36, 1.86) for coagulation complications, and 2.42 (2.01, 2.92) for renal injury. For most complications, a modifying effect of age was observed, with higher odds of complications at higher glucose levels for patients age <69 years. Preexisting diabetes status had a similar modifying effect on odds of complications, but evidence was strongest for renal injury, cardiac ischemia, and any cardiovascular/renal complication.CONCLUSIONS: Increased odds of cardiovascular or renal complications were observed for admission glucose levels indicative of both hypo- and hyperglycemia. Admission glucose could be used as a marker for risk stratification of high-risk patients. Further research should evaluate interventions to optimize admission glucose on improving COVID-19 outcomes.
KW - Adult
KW - Aged
KW - Blood Glucose
KW - COVID-19/complications
KW - Heart Failure
KW - Humans
KW - Ischemia
KW - Kidney
KW - Prospective Studies
KW - Stroke/epidemiology
U2 - 10.2337/dc21-1709
DO - 10.2337/dc21-1709
M3 - Article
C2 - 35275994
SN - 0149-5992
VL - 45
SP - 1132
EP - 1140
JO - Diabetes Care
JF - Diabetes Care
IS - 5
ER -